MedTrace Logo

International Multicentric Study ARON-1

NCT05287464 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1220

Last updated 2025-11-26

No results posted yet for this study

Summary

The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.

Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations

Conditions

  • Metastatic Renal Cell Carcinoma (mRCC)

Interventions

DRUG

pembrolizumab plus axitinib

collect global experiences with the use of immuno-combinations in patients with metastatic RCC

Sponsors & Collaborators

  • Hospital of Macerata

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2024-06-01
Completion
2027-09-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287464 on ClinicalTrials.gov